PL3322722T3 - Środki, zastosowania i sposoby leczenia synukleinopatii - Google Patents
Środki, zastosowania i sposoby leczenia synukleinopatiiInfo
- Publication number
- PL3322722T3 PL3322722T3 PL16738736.4T PL16738736T PL3322722T3 PL 3322722 T3 PL3322722 T3 PL 3322722T3 PL 16738736 T PL16738736 T PL 16738736T PL 3322722 T3 PL3322722 T3 PL 3322722T3
- Authority
- PL
- Poland
- Prior art keywords
- synucleinopathy
- agents
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512203.9A GB201512203D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| PCT/EP2016/066476 WO2017009312A1 (en) | 2015-07-13 | 2016-07-12 | Agents, uses and methods for the treatment of synucleinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3322722T3 true PL3322722T3 (pl) | 2025-06-30 |
Family
ID=54013851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16738736.4T PL3322722T3 (pl) | 2015-07-13 | 2016-07-12 | Środki, zastosowania i sposoby leczenia synukleinopatii |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AU2017359944B2 (en) * | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| MX2019008029A (es) | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| US10799484B2 (en) * | 2017-03-27 | 2020-10-13 | Chase Therapeutics Corporation | Compositions and methods for treating synucleinopathies |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| US11155608B2 (en) | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| KR102508933B1 (ko) * | 2017-11-17 | 2023-03-13 | 에이비엘바이오 주식회사 | 알파-시누클레인에 대한 항체 및 그 용도 |
| CN116731173A (zh) | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| MX2020007904A (es) | 2018-01-26 | 2020-09-07 | Quantum Si Inc | Llamado de pulso y base habilitado por maquina de aprendizaje para dispositivos de secuenciacion. |
| EP3752840A4 (en) * | 2018-02-12 | 2022-08-10 | The Scripps Research Institute | PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES |
| WO2020033756A1 (en) * | 2018-08-09 | 2020-02-13 | F. Hoffmann-La Roche Ag | Determination of parkinson's disease |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| WO2020212593A1 (en) * | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| EP3962492A4 (en) * | 2019-04-29 | 2023-05-31 | Thomas Jefferson University | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP2023504699A (ja) * | 2019-12-04 | 2023-02-06 | エイシー イミューン ソシエテ アノニム | 治療および診断のための新規な分子 |
| KR102466943B1 (ko) * | 2020-04-02 | 2022-11-14 | 한국과학기술연구원 | 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템 |
| CN111537738A (zh) * | 2020-05-18 | 2020-08-14 | 南通大学附属医院 | 用于超早期帕金森病检测的试剂盒 |
| KR20240055785A (ko) * | 2021-09-01 | 2024-04-29 | 백시니티, 인크. | 시누클레인병증의 방지 및 치료 방법 |
| IL311344A (en) | 2021-09-16 | 2024-05-01 | H Lundbeck As | Preparations and methods for the treatment of synoclinopathies |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| WO2024177999A2 (en) * | 2023-02-21 | 2024-08-29 | The Regents Of The University Of Michigan | Human aggregated alpha-synuclein binding molecules |
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
| WO2025076635A1 (en) * | 2023-10-12 | 2025-04-17 | Universite Laval | Anti-alpha-synuclein antibodies and uses thereof |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1512203A (en) | 1974-05-08 | 1978-05-24 | Aspin F | Rolls for use in profiling film |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988004777A1 (en) | 1986-12-15 | 1988-06-30 | Ultra Diagnostics Corporation | Monomeric phthalocyanine reagents |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CN1440420A (zh) | 2000-07-07 | 2003-09-03 | 万能药制药公司 | 预防神经组织损伤和治疗α－共核蛋白疾病的方法 |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| WO2003000714A2 (en) | 2001-06-22 | 2003-01-03 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US8829198B2 (en) | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| DK1633189T3 (en) | 2003-05-19 | 2017-08-21 | Prothena Biosciences Ltd | TRUNCTED FRAGMENTS OF ALFA SYNUCLEIN IN LEWY BODY DISEASE |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2006031250A (ja) | 2004-07-14 | 2006-02-02 | Fuji Xerox Co Ltd | 通信装置およびその制御方法 |
| EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| US20060205024A1 (en) | 2005-03-08 | 2006-09-14 | Sun Health Research Institute | Method to diagnose and evaluate progression of Alzheimer's disease |
| US20080300204A1 (en) * | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| PT3067066T (pt) | 2007-02-23 | 2019-06-17 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
| DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| WO2010118282A1 (en) | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| LT2723379T (lt) * | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| JP2013059866A (ja) | 2011-09-12 | 2013-04-04 | Seiko Epson Corp | 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム |
| LT2771031T (lt) * | 2011-10-28 | 2018-08-27 | Prothena Biosciences Limited | Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną |
| WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| MX2017014191A (es) | 2015-05-07 | 2018-08-01 | Axovant Sciences Gmbh | Metodos de tratamiento de una enfermedad neurodegenerativa. |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| KR102499438B1 (ko) | 2016-06-02 | 2023-02-14 | 메디뮨 리미티드 | 알파-시누클레인에 대한 항체 및 이의 용도 |
| AU2017359944B2 (en) | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2015
- 2015-07-13 GB GBGB1512203.9A patent/GB201512203D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0140A patent/JO3692B1/ar active
- 2016-07-12 KR KR1020257011170A patent/KR20250051158A/ko active Pending
- 2016-07-12 MY MYPI2017001926A patent/MY194944A/en unknown
- 2016-07-12 JP JP2018501163A patent/JP7012004B2/ja active Active
- 2016-07-12 ES ES16738736T patent/ES3028882T3/es active Active
- 2016-07-12 AU AU2016292896A patent/AU2016292896B2/en active Active
- 2016-07-12 EA EA201792616A patent/EA036499B1/ru not_active IP Right Cessation
- 2016-07-12 TW TW105121902A patent/TWI729992B/zh active
- 2016-07-12 GE GEAP201614670A patent/GEP20207151B/en unknown
- 2016-07-12 MA MA42439A patent/MA42439B1/fr unknown
- 2016-07-12 HR HRP20250624TT patent/HRP20250624T1/hr unknown
- 2016-07-12 LT LTEPPCT/EP2016/066476T patent/LT3322722T/lt unknown
- 2016-07-12 CA CA2989735A patent/CA2989735A1/en active Pending
- 2016-07-12 CN CN202210997939.4A patent/CN115925921A/zh active Pending
- 2016-07-12 RU RU2017145653A patent/RU2765303C2/ru active
- 2016-07-12 PL PL16738736.4T patent/PL3322722T3/pl unknown
- 2016-07-12 US US15/207,859 patent/US10800836B2/en active Active
- 2016-07-12 CR CR20230300A patent/CR20230300A/es unknown
- 2016-07-12 EP EP16738736.4A patent/EP3322722B1/en active Active
- 2016-07-12 PT PT167387364T patent/PT3322722T/pt unknown
- 2016-07-12 TN TNP/2018/000005A patent/TN2018000005A1/en unknown
- 2016-07-12 CR CR20180021A patent/CR20180021A/es unknown
- 2016-07-12 SI SI201631902T patent/SI3322722T1/sl unknown
- 2016-07-12 CN CN201680039417.6A patent/CN107709361A/zh active Pending
- 2016-07-12 UA UAA201800664A patent/UA125501C2/uk unknown
- 2016-07-12 KR KR1020177037733A patent/KR102793383B1/ko active Active
- 2016-07-12 HU HUE16738736A patent/HUE071541T2/hu unknown
- 2016-07-12 AR ARP160102110A patent/AR105336A1/es unknown
- 2016-07-12 EP EP25154059.7A patent/EP4582144A3/en active Pending
- 2016-07-12 RS RS20250497A patent/RS66840B1/sr unknown
- 2016-07-12 WO PCT/EP2016/066476 patent/WO2017009312A1/en not_active Ceased
- 2016-07-12 DK DK16738736.4T patent/DK3322722T3/da active
- 2016-07-12 FI FIEP16738736.4T patent/FI3322722T3/fi active
- 2016-07-12 MX MX2018000504A patent/MX2018000504A/es unknown
- 2016-07-12 PE PE2018000066A patent/PE20181049A1/es unknown
-
2017
- 2017-11-14 US US15/812,363 patent/US10364285B2/en active Active
- 2017-11-14 US US15/812,251 patent/US10358482B2/en active Active
- 2017-11-14 US US15/812,303 patent/US10358483B2/en active Active
- 2017-11-14 US US15/812,410 patent/US10358484B2/en active Active
- 2017-12-15 CO CONC2017/0012941A patent/CO2017012941A2/es unknown
- 2017-12-18 ZA ZA2017/08607A patent/ZA201708607B/en unknown
- 2017-12-22 IL IL256501A patent/IL256501B/en unknown
-
2018
- 2018-01-03 PH PH12018500016A patent/PH12018500016A1/en unknown
- 2018-01-09 CL CL2018000075A patent/CL2018000075A1/es unknown
- 2018-01-11 NI NI201800006A patent/NI201800006A/es unknown
- 2018-01-11 SV SV2018005612A patent/SV2018005612A/es unknown
- 2018-01-11 DO DO2018000013A patent/DOP2018000013A/es unknown
- 2018-01-12 EC ECIEPI20182645A patent/ECSP18002645A/es unknown
- 2018-01-12 MX MX2023009483A patent/MX2023009483A/es unknown
-
2019
- 2019-06-17 US US16/443,225 patent/US10647764B2/en active Active
- 2019-06-17 US US16/443,249 patent/US10640554B2/en active Active
- 2019-06-17 US US16/443,187 patent/US10647763B2/en active Active
-
2020
- 2020-06-08 US US16/895,471 patent/US11524995B2/en active Active
- 2020-08-27 US US17/004,447 patent/US11421024B2/en active Active
- 2020-11-03 US US17/088,307 patent/US11542323B2/en active Active
-
2021
- 2021-08-24 JP JP2021136539A patent/JP7138322B2/ja active Active
-
2022
- 2022-08-29 JP JP2022136108A patent/JP7608404B2/ja active Active
- 2022-11-22 US US17/992,403 patent/US20230312693A1/en active Pending
-
2024
- 2024-12-18 JP JP2024221962A patent/JP2025041734A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| IL266596A (en) | Causes, uses and methods of treating synovialitis | |
| IL279627A (en) | A method for treating depression | |
| IL269371A (en) | Treatment methods | |
| ZA201705673B (en) | Methods for treating skin | |
| IL258002A (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| PL3286311T3 (pl) | Sposób leczenia nowotworów złośliwych | |
| GB2588261B (en) | Apparatus, use of the apparatus and arrangement | |
| GB201502137D0 (en) | Treatment | |
| PT3261726T (pt) | Composição para o tratamento do acne | |
| GB201608885D0 (en) | Treatment | |
| GB201512215D0 (en) | Agents,uses and methods | |
| GB201522243D0 (en) | Treatment | |
| IL271728A (en) | Materials, uses and treatment methods | |
| IL252197A0 (en) | A method for treating, preventing or reducing the risk of skin infection | |
| IL258137B1 (en) | HIV treatment measures | |
| IL253617A0 (en) | Snekribirock for the treatment of leprosy | |
| GB201508841D0 (en) | Treatment | |
| GB201503008D0 (en) | Treatment | |
| HK40013476A (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| GB201518375D0 (en) | Agents,uses and methods | |
| GB201609683D0 (en) | Treatment |